CA2387013C — 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2009-12-29 · 16y expired
What this patent protects
The present invention relates to indolinones of general formula (see formula I) substituted in the 6 position, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory eff…
USPTO Abstract
The present invention relates to indolinones of general formula (see formula I) substituted in the 6 position, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.